SG11202104115SA - Methods of treating graves' ophthalmopathy using anti-fcrn antibodies - Google Patents

Methods of treating graves' ophthalmopathy using anti-fcrn antibodies

Info

Publication number
SG11202104115SA
SG11202104115SA SG11202104115SA SG11202104115SA SG11202104115SA SG 11202104115S A SG11202104115S A SG 11202104115SA SG 11202104115S A SG11202104115S A SG 11202104115SA SG 11202104115S A SG11202104115S A SG 11202104115SA SG 11202104115S A SG11202104115S A SG 11202104115SA
Authority
SG
Singapore
Prior art keywords
ophthalmopathy
methods
fcrn antibodies
treating graves
graves
Prior art date
Application number
SG11202104115SA
Other languages
English (en)
Inventor
Regan Fong
Melissa Polasek
Christine Coquery
Original Assignee
Immunovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovant Sciences Gmbh filed Critical Immunovant Sciences Gmbh
Publication of SG11202104115SA publication Critical patent/SG11202104115SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202104115SA 2018-11-06 2019-11-05 Methods of treating graves' ophthalmopathy using anti-fcrn antibodies SG11202104115SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862756472P 2018-11-06 2018-11-06
PCT/US2019/059894 WO2020097099A1 (fr) 2018-11-06 2019-11-05 Méthodes de traitement de l'ophtalmopathie de graves faisant appel à des anticorps anti-fcrn

Publications (1)

Publication Number Publication Date
SG11202104115SA true SG11202104115SA (en) 2021-05-28

Family

ID=68655771

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104115SA SG11202104115SA (en) 2018-11-06 2019-11-05 Methods of treating graves' ophthalmopathy using anti-fcrn antibodies

Country Status (17)

Country Link
US (1) US20220002402A1 (fr)
EP (1) EP3876985A1 (fr)
JP (1) JP7489978B2 (fr)
KR (1) KR20210089214A (fr)
CN (1) CN113423426A (fr)
AU (1) AU2019374780A1 (fr)
BR (1) BR112021008778A2 (fr)
CA (1) CA3118777A1 (fr)
CL (1) CL2021001201A1 (fr)
CO (1) CO2021007053A2 (fr)
EA (1) EA202191231A1 (fr)
IL (1) IL282795A (fr)
MX (1) MX2021005323A (fr)
SG (1) SG11202104115SA (fr)
TW (1) TW202031287A (fr)
WO (1) WO2020097099A1 (fr)
ZA (1) ZA202103035B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240287191A1 (en) * 2020-06-29 2024-08-29 Hanall Biopharma Co., Ltd. Formulation for anti-fcrn antibody
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability
WO2024006942A1 (fr) * 2022-06-29 2024-01-04 Lirum Therapeutics, Inc. Procédés de traitement d'états inflammatoires de l'œil avec un ligand du récepteur du facteur de croissance 1 de type insuline conjugué à un agent de modification de maladie
WO2024052357A1 (fr) * 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Méthodes de traitement de la maladie de graves à l'aide d'anticorps anti-fcrn
WO2024052358A1 (fr) * 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Méthodes de traitement d'une polyneuropathie démyélinisante inflammatoire chronique à l'aide d'anticorps anti-fcrn
WO2024163894A1 (fr) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions et méthodes de traitement d'une maladie hémolytique du fœtus et du nouveau-né

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
CA2945086C (fr) * 2014-04-30 2020-12-29 Hanall Biopharma Co., Ltd. Anticorps se liant a fcrn pour le traitement de maladies auto-immunes
CN114716550A (zh) * 2015-05-12 2022-07-08 Synt免疫公司 人源化亲和力成熟的抗FcRn抗体
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
BR112021008778A2 (pt) 2021-08-31
IL282795A (en) 2021-06-30
MX2021005323A (es) 2021-08-24
JP2022512967A (ja) 2022-02-07
TW202031287A (zh) 2020-09-01
CO2021007053A2 (es) 2021-08-19
CA3118777A1 (fr) 2020-05-14
CL2021001201A1 (es) 2022-02-11
ZA202103035B (en) 2022-03-30
JP7489978B2 (ja) 2024-05-24
KR20210089214A (ko) 2021-07-15
EP3876985A1 (fr) 2021-09-15
EA202191231A1 (ru) 2021-10-11
AU2019374780A1 (en) 2021-05-27
CN113423426A (zh) 2021-09-21
US20220002402A1 (en) 2022-01-06
WO2020097099A1 (fr) 2020-05-14

Similar Documents

Publication Publication Date Title
ZA202103035B (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
SG11202104222TA (en) Method of treatment of biological surfaces
IL283948A (en) Methods for treating depression
EP3762015A4 (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
EP3873478A4 (fr) Procédé d'amélioration d'une immunothérapie
SG11202010793UA (en) Methods of treating cancer
GB2584105B (en) Methods of treating neuropathy
ZA202203776B (en) Methods of treating epilepsy using the same
IL290816A (en) Anti-latent tgf-beta 1 cross-species antibodies and methods of use
IL277981A (en) Cancer treatment methods
IL258515A (en) Treatment methods using anti-il-17a/f antibodies
IL290770A (en) Compounds and methods for treating oxalate-related diseases
IL287759A (en) Treatment of headaches using anti-cgrp antibodies
IL281600A (en) Methods of treating cancer
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
IL287250A (en) Method of treatment
IL286099A (en) Methods of treating the disease using levoketoconazole
IL281284A (en) Psoriasis treatment methods
IL277962A (en) Methods for treating neuropathic pain
IL268111A (en) Methods of treating pain
SG11202105877YA (en) Method of treatment
IL290983A (en) Treatment methods
IL290853A (en) Treatment methods using omelizumab
GB201918853D0 (en) Methods of treatment
GB201900942D0 (en) Methods of treatment